Skip to content

Clinical trials

Phase 2/3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive Phase: Phase 2/3 Clear all

12 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20041
20051
20062
20071
20092
20141

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed7
Terminated2
Unknown status2
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Amneal Pharmaceuticals, LLC1
Ann & Robert H Lurie Children's Hospital of Chicago1
Bristol-Myers Squibb1
Gamida Cell -Teva Joint Venture Ltd.1
Gruppo Italiano Trapianto di Midollo Osseo1
Hoffmann-La Roche1
M.D. Anderson Cancer Center1
Merck Sharp & Dohme LLC1
Novartis Pharmaceuticals1
Rambam Health Care Campus1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive12
Precursor Cell Lymphoblastic Leukemia-Lymphoma6
Leukemia, Myeloid, Acute4
Leukemia2
Myelodysplastic Syndromes2
Anemia, Refractory, with Excess of Blasts1
Bronchiolitis Obliterans Syndrome1
Carcinoma, Renal Cell1
Gastrointestinal Stromal Tumors1
Hematologic Neoplasms1

Trials

Showing 76 to 12 of 12. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.